Enhancement by IL-12 of the cytolytic T lymphocyte (CTL) response of mice immunized with tumor-specific peptides in an adjuvant containing QS21 and MPL

European Cytokine Network

Volumn 10, Issue 2, 1999, Pages 181-189

  Silla, Silvia ^a   Fallarino, Francesca ^b   Boon, Thierry ^a   Uyttenhove, Catherine ^a,c  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

Author keywords

CTL induction; IL 12; Mouse tumor specific antigens; Peptide vaccination; QS21 MPL adjuvant

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 7; LIPID A DERIVATIVE; MACROPHAGE CHEMOTACTIC FACTOR; QS 21; TUMOR ANTIGEN; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER IMMUNIZATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; INTRADERMAL DRUG ADMINISTRATION; MASTOCYTOMA; MOUSE; NONHUMAN; SUBCUTANEOUS DRUG ADMINISTRATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CYTOTOXICITY TESTS, IMMUNOLOGIC; DRUG SYNERGISM; EAR, EXTERNAL; FEMALE; H-2 ANTIGENS; HINDLIMB; HISTOCOMPATIBILITY ANTIGENS; IMMUNOTHERAPY, ACTIVE; INJECTIONS, SUBCUTANEOUS; INTERFERON TYPE II; INTERLEUKIN-12; LIPID A; LYMPHOCYTE ACTIVATION; MAST-CELL SARCOMA; MICE; MICE, INBRED DBA; ORGAN SPECIFICITY; PEPTIDE FRAGMENTS; SAPONINS; SPECIFIC PATHOGEN-FREE ORGANISMS; T-LYMPHOCYTES, CYTOTOXIC; TAIL; TUMOR CELLS, CULTURED;

ANIMALIA;

EID: 0032811979     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. 1. Van den Eynde B J, van der Bruggen P. 1997. T cell-defined tumor antigens. (Review) Curr. Opin. Immunol. 9: 684.
2. 2. Coulie P G, Lehmann F, Lethé B, Herman J, Lurquin C, Andrawiss M, Boon T. 1995. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc. Natl. Acad. Sci. USA 92: 7976.
3. INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269: 1281.
4. 4. Robbins P F, El-Gamil M, Li Y F, Kawakami Y, Loftus D, Appella E, Rosenberg S A, 1996. A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med. 183: 1185.
5. 5. Uyttenhove C, Van Snick J, Boon T. 1980. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. I. Rejection by syngeneic mice. J. Exp. Med. 152: 1175.
6. 6. Sibille C, Chomez P, Wildmann C, Van Pel A, De Plaen E, Maryanski J L, de Bwrgeyck V, Boon T. 1990. Structure of the gene of tum-transplantation antigen P198: a point mutation generates a new antigenic peptide. J. Exp. Med. 172: 35.
7. 7. Uyttenhove C, Maryanski J, Boon T. 1983. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J. Exp. Med. 157: 1040.
8. 8. Uyttenhove C, Godfraind C, Lethé B, Amar-Costesec A, Renauld J C, Gajewski T F, Duffour T, Warnier G, Boon T, van den Eynde B J. 1997. The expression of mouse gene P1A in testis does not prevent safe induction of cytolytic T cells against a P1A-encoded tumor antigen. Int. J. Cancer 70: 349.
9. 9. Boon T, van den Eynde B, Hirsch H, Moroni C, De Plaen E, van der Bruggen P, De Smet C, Lurquin C, Szikora J P, De Backer O. 1994. Genes coding for tumor-specific rejection antigens. Cold Spring Harbor Symposia on Quantitative Biology: Molecular Genetics of Cancer: 617.
10. 10. Ramarathinam L, Sarma S, Maric M, Zhao M, Yang G, Chen L, Liu Y. 1995. Multiple lineages of tumors express a common tumor antigen, P1A, but they are not cross-protected. J. Immunol. 155: 5323.
11. 11. Van den Eynde B, Lethé B, van Pel A, de Plaen E, Boon T. 1991. The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J. Exp. Med. 173: 1373.
12. 12. Lethé B, van den Eynde B, van Pel A, Corradin G, Boon T, 1992. Mouse tumor rejection antigens P815A and P815B: two epitopes carried by a single peptide. Eur. J. Immunol. 22: 2283.
13. 13. Van Pel A, de Plaen E, Boon T. 1985. Selection of a highly transfectable variant from mouse mastocytoma P815. Somat. Cell. Mol. Genet. 11: 467.
14. 14. Atherton E, Logan C J, Sheppard R C. 1981. Peptide synthesis. Part 2. Procedures for solid phase synthesis using Na-fluoronylmethysoxy-carbamylamino-acid on polymide supports. Synthesis of substance P and of acyl carrier protein 65-74 deca-peptide. J. Chem. Soc. Lond. Perkin Trans. 1: 538.
15. 15. Simpson R J, Moritz R L, van Roost E, van Snick J. 1988. Characterization of a recombinant murine IL-6: assignment of disulfide bonds. Biochem. Biophys. Res. Commun. 157: 364.
16. 16. Simpson R J, Moritz R L, Rubira M R, van Snick J. 1988. Murine hybridoma/plasmacytoma growth factor. Complete amino-acid sequence and relation to human interleukin-6. Eur. J. Biochem. 176: 187.
17. 17. Van Snick J, Cayphas S, Vink A, Uyttenhove C, Coulie P G, Rubira M R, Simpson R J. 1986. Purification and NH2-terminal amino acid sequence of a T cell-derived lymphokine with growth factor activity for B cell hybridomas. Proc. Natl. Acad. Sci. USA 83: 9679.
18. 18. Gajewski T F, Renauld J C, van Pel A, Boon T. 1995. Costimulation with B7-1, IL-6, and IL-12 is sufficient for primary generation of murine anti-tumor cytolytic T lymphocytes in vitro. J. Immunol. 154: 5637.
19. 19. Gajewski T F, Fallarino F, Uyttenhove C, Boon T. 1996. Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization. J. Immunol. 156: 2909.
20. 20. Wysocka M, Kubin M, Viera L Q, Ozmen L, Garotta G, Scott P, Trinchieri G. 1995. Interleukin-12 is required for interferon-γ production and lethality in lipopolysaccharide-induced shock in mice. Eur. J. Immunol. 25: 672.
21. 21. Schoenhaut D S, Chua A O, Wolitsky A G, Quinn P M, Dwyer C M, McComas W, Familletti P C, Gately M K, Gubler U. 1992. Cloning and expression of murine IL-12. J. Immunol. 148: 3433.
22. 22. Fallarino F, Uyttenhove C, Boon T, Gajewski T F. 1999. Improved efficacy of dendritic cell vaccines and successful immunization with tumor antigen peptide-pulsed peripheral blood mononuclear cells by coadministation of recombinant murine interleukin-12. Int. J. Cancer 80:324.
23. 23. Bianchi R, Grohmann U, Belladonna M L, Silla S, Fallarino F, Ayroldi E, Fioretti M C, Pucetti P. 1996. IL-12 is both required and sufficient for initiating T cell reactivity to a class I-restricted tumor peptide (P815AB) following transfer of P815AB-pulsed dendritic cells. J. Immunol. 157: 1589.
24. 24. Kyburz D, Aichele P, Speiser D E, Hengartner H, Zinkernagel R M, Pircher H. 1993. T cell immunity after a viral infection versus T cell tolerance induced by soluble viral peptides. Eur. J. Immunol. 23: 1956.
25. 25. Toes R E, Blom R J, Offringa R, Kast W M, Melief C J. 1996. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. J. Immunol. 156: 3911.
26. 26. Boon T, van Snick J, van Pel A, Uyttenhove C, Marchand M. 1980. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis. J. Exp. Med. 152: 1184.
27. 27. Trinchieri G. 1995. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. (Review) Annu. Rev. Immunol. 13: 251.
28. 28. Gresser I, Belardelli F, Maury C, Tovey M G, Maunoury M T. 1986. Anti-tumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant friend leukemia cells. IV. Definition of optimal treatment regimens. Int. J. Cancer 38: 251.
29. 29. Hioe C E, Qui H, Chend P D, Bian Z N, Li M L, Li J, Singh M, Kuebler P, McGee P, O'Hagan D, Zamb T, Koff W, Allsopp C, Wang C Y, Nixon D F. 1996. Comparison of adjuvant formulations for cytotoxic T cell induction using synthetic peptides. Vaccine 14: 412.
30. 30. Hurpin C, Rotarioa C, Bisceglia H, Chevalier M, Tartaglia J, Erdile L. 1998. The mode of presentation and route of administration are critical for the induction of immune responses to p53 and antitumor immunity. Vaccine 16: 208.
31. 31. Kast W M, Roux L, Curren J, Blom H J, Voordouw A C, Meloen R H, Kolakofsky D, Melief C J. 1991. Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide. Proc. Natl. Acad. Sci. USA 88: 2283.
32. 32. Schulz M, Zinkernagel R M, Hengartner H. 1991. Peptide-induced antiviral protection by cytotoxic T cells. Proc. Natl. Acad. Sci. USA 88: 991.
33. 33. Zhou X, Berg L, Motal U M, Jondal M. 1992. In vivo primary induction of virus-specific CTL by immunization with 9-mer synthetic peptides. J. Immunol. Methods 153: 193.
34. 34. Franke E D, Corradin G, Hoffman S L. 1997. Induction of protective CTL responses against the Plasmodium yoelii circumsporozoite protein by immunization with peptides. J. Immunol. 159: 3424.
35. 35. Wu J Y, Gardner B H, Murphy C I, Seals J R, Kensil C R, Recchia J, Beltz G A, Newman G W, Newman M J. 1992. Saponin adjuvant enhancement of antigen-specific immune response to an experimental HIV-1 vaccine. J. Immunol. 148: 1519.
36. 36. Noguchi Y, Richards E C, Chen Y T, Old L J. 1995. Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc. Natl. Acad. Sci. USA 92: 2219.
37. 37. Kensil C R, Soltysik S, Wheeler D A, Wu J Y. 1996. Structure/function studies on QS-21, a unique immunological adjuvant from Quillaja Saponaria. In: Waller, Yamasaki, eds. Saponins Used in Traditionnal and Modern Medicine, New York: Plenum Press: 165.
38. 38. Wu J Y, Gardner B H, Kushner N N, Pozzi L M, Kensil C R, Cloutier P A, Coughlin R T, Newman M J. 1994. Accessory cell requirements for saponin adjuvant-induced class 1 MHC antigen-restricted cytotoxic T lymphocytes. Cell Immunol. 154: 393.
39. 39. Kensil C R, Newman M J, Coughlin R T, Soltysik S, Bedore D, Recchia J, Wu J, Marciani D J. 1993. The use of Stimulon adjuvant to boost vaccine response. Vaccine Research 2: 273.
40. 40. Neuzil K M, Johnson J E, Tang Y W, Prieels J P, Slaoui M, Gar N, Graham B S. 1997. Adjuvants influence the quantitative and qualitative immune response in BALB/c mice immunized with respiratory syncytial FG subunit vaccine. Vaccine 5: 525.
41. 41. Kensil C R, Patel U, Lennick M, Marciani D. 1991. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J. Immunol. 146: 431.
42. 42. Valensi J P, Carlson J R, van Nest G A. 1994. Systemic cytokine profiles in BALB/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants. J. Immunol. 153: 4029.
43. 43. Ribi E. 1984. Beneficial modification of the endotoxin molecule. J. Biol. Response Mod. 3: 1.
44. 44. Kubin M, Kamoun M, Trinchieri G, 1994. Interleukin-12 synergizes with B7/CD28 interaction in inducing efficient proliferation and cytokine production of human T cells. J. Exp. Med. 180: 211.
45. 45. Kurzawa H, Wysocka M, Aruga E, Chang A E, Trinchieri G, Lee W M. 1998. Recombinant interleukin 12 enhances cellular immune responses to vaccination only after a period of suppression. Cancer Res. 58: 491.
46. 46. Koblish H K, Hunter C A, Wysocka M, Trinchieri G, Lee W M. 1998. Immune suppression by recombinant interleukin (rIL)-12 involves interferon-gamma induction of nitric oxide synthase 2 (iNOS) activity: inhibitors of NO generation reveal the extent of rIL-12 vaccine adjuvant effect. J. Exp. Med. 188: 1603.
47. 47. Warnier G, Duffour M T, Uyttenhove C, Lurquin C, Haddada H, Perricaudet M, Boon T. 1996. Induction of a cytolytic T cell response in mice with a recombinant adenovirus coding for tumor antigen P815A. Int. J. Cancer 67: 303.